In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.Q: How does the new indication expand the eligible patient population?
Reviews (10) Dosage information Patient tips During pregnancy Drug class: miscellaneous antihyperlipidemic agents Breastfeeding En español Patient resources Bempedoic acid drug information Other brands Nexletol Professional resources Bempedoic Acid monograph Other brands Nexletol Related treatment guides Hi...
Conclusion: Bempedoic acid may reduce the risk of cardiovascular events regardless of whether the patient is taking stains or not. Registration: PROSPERO registration number CRD42023422932.doi:10.1007/s40256-023-00606-4Zhang, JuGuan, Xiangfeng
the elevations were transient and resolved or improved with continued therapy or after discontinuation of therapy. Increases to more than 3× the upper limit of normal (ULN) in AST occurred in 1.4% of patients treated with bempedoic acid versus 0.4% of placebo patients, and increases...
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trialsdoi:10.1016/j.atherosclerosis.2020.10.050P.B. DuellM. BanachA.L. CatapanoU. Laufs...
In this case study, we describe a patient with HeFH who had a prior excellent response to statin but unable to take the same, and a less than expected response to PCSK9i, in whom initiation of bempedoic acid led to a substantial reduction of LDL-C. Our findings suggest that patients ...
FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALSdoi:10.1016/S0735-1097(20)32543-2Erik S. G StroesHarold BaysMaciej BanachAlberico Catapano...
One patient in the atorvastatin/bempedoic acid group had elevated creatine phosphokinase levels on day 14. CPK values returned to normal by day 21. This event was not considered clinically significant or related to the study drug by the investigator, the patient did not report any associated ...
Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trialsdoi:10.1016/j.jacl.2020.05.056Erik StroesHarold BaysMaciej BanachAlberico Catapano